Item 8.01 Other Events

On December 22, 2021, the Company issued a press release announcing that the first patient has been dosed in its Phase 2 proof-of-concept clinical study (NCT04874350) with LPCN 1148 for the management of liver cirrhosis. The press release is filed as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d)    Exhibits

The following exhibits are filed with this report:

Exhibit No.   Description

99.1            Press Release announcing Patient Dosed in Phase 2 Study with LPCN
              1148 for the Management of Liver Cirrhosis

104           Cover Page Interactive Data File (embedded within the Inline XBRL
              document)

© Edgar Online, source Glimpses